Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empirical versus pre-emptive caspofungin strategy in neutropenic patients with hematologic malignancies
NL-OMON57812Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2012
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of caspofungin in invasive mycoses (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival at 42 days. Started May 2012; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive mycoses
Beyond the preview
Go deeper on NL-OMON57812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57812.